Crossmark

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Crossref DOI link: https://doi.org/10.1016/S0140-6736(16)31408-8

Published Print: 2016-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Finkel, Richard S

Chiriboga, Claudia A

Vajsar, Jiri

Day, John W

Montes, Jacqueline

De Vivo, Darryl C

Yamashita, Mason

Rigo, Frank

Hung, Gene

Schneider, Eugene

Norris, Daniel A

Xia, Shuting

Bennett, C Frank

Bishop, Kathie M
License Information

Text and Data Mining valid from 2016-12-01
More Information

This article is maintained by: Elsevier

Article Title: Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Journal Title: The Lancet

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(16)31408-8

CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(16)32390-X

Content Type: article

Copyright: © 2016 Elsevier Ltd. All rights reserved.